Yu Shao-Long, Zhou Fang-Jian, Qin Zi-Ke, Han Hui, Liu Zhuo-Wei, Wang Bin, Wang Huan, Li Yong-Hong
State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China.
Ai Zheng. 2006 Jan;25(1):73-5.
BACKGROUND & OBJECTIVE: Bladder transitional cell carcinoma (TCC) is the most common cancer among urogenital neoplasms. Surgical operation is the most effective therapy for TCC. This study was to explore surgical treatment for TCC and its clinical significance.
Clinical data, including disease-free survival, recurrence and death, of 217 TCC patients who had received different surgical procedures were retrospectively analyzed.
After a median follow-up of 30 months, 195 patients were free of disease, recurrence was observed for 56 times. Fourteen patients died: 13 of them died of progressive disease, and 1 died of renal failure. None death occurred in patients with stage T1 or grade I tumor. The overall 2-year survival rate was 89.6%. The survival rate and disease-freely survival rate were negatively correlated to stage and grade of the tumors. The prognosis of stage T1 and T4 patients had no correlation to surgical procedures. For stage T2 and T3 tumors, the prognosis of the patients who received radical cystectomy was significantly better than that of the patients who received organ sparing procedure.
The organ sparing treatment is safe for patients with early stage and well differentiated TCC. Radical cystectomy should be done in time for patients with advanced and poorly differentiated TCC.
